"Fibrinolysin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins.
Descriptor ID |
D005341
|
MeSH Number(s) |
D08.811.277.656.300.760.330 D08.811.277.656.959.350.330
|
Concept/Terms |
Fibrinolysin- Fibrinolysin
- Plasmin
- Protease F
- Glu-Plasmin
- Glu Plasmin
|
Below are MeSH descriptors whose meaning is more general than "Fibrinolysin".
Below are MeSH descriptors whose meaning is more specific than "Fibrinolysin".
This graph shows the total number of publications written about "Fibrinolysin" by people in this website by year, and whether "Fibrinolysin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2000 | 1 | 0 | 1 |
2008 | 1 | 0 | 1 |
2009 | 0 | 1 | 1 |
2010 | 1 | 0 | 1 |
2012 | 1 | 0 | 1 |
2013 | 1 | 0 | 1 |
2014 | 1 | 0 | 1 |
2015 | 8 | 0 | 8 |
2016 | 1 | 0 | 1 |
2018 | 2 | 0 | 2 |
2020 | 1 | 1 | 2 |
2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fibrinolysin" by people in Profiles.
-
Jackson TL, Haller J, Blot KH, Duchateau L, Lescrauwaet B. Ocriplasmin for treatment of vitreomacular traction and macular hole: A systematic literature review and individual participant data meta-analysis of randomized, controlled, double-masked trials. Surv Ophthalmol. 2022 May-Jun; 67(3):697-711.
-
Mein C, Dugel PU, Feiner L, Drenser K, Miller D, Benz M, Meunier E, Moro L, Fineman MS. PATIENT-REPORTED VISUAL FUNCTION FROM THE OCRIPLASMIN FOR TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION, INCLUDING MACULAR HOLE (OASIS) STUDY. Retina. 2020 Jul; 40(7):1331-1338.
-
Khanani AM, Dugel PU, Haller JA, Wagner AL, Lescrauwaet B, Schmidt R, Bennison C. Cost-effectiveness analysis of ocriplasmin versus watchful waiting for treatment of symptomatic vitreomacular adhesion in the US. J Comp Eff Res. 2020 03; 9(4):287-305.
-
Yu TM, Dugel PU, Haller JA, Kaiser PK, Arnold RJ. Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA. J Comp Eff Res. 2018 12; 7(12):1195-1207.
-
Birch DG, Benz MS, Miller DM, Antoszyk AN, Markoff J, Kozma P, Meunier E, Sergott RC. EVALUATION OF FULL-FIELD ELECTRORETINOGRAM REDUCTIONS AFTER OCRIPLASMIN TREATMENT: Results of the OASIS Trial ERG Substudy. Retina. 2018 Feb; 38(2):364-378.
-
Jackson TL, Regillo CD, Girach A, Dugel PU. Baseline Predictors of Vitreomacular Adhesion/Traction Resolution Following an Intravitreal Injection of Ocriplasmin. Ophthalmic Surg Lasers Imaging Retina. 2016 08 01; 47(8):716-23.
-
Greven MA, Garg S, Chiu B, Shah SP, Wolfe J, Fine HF, Roth DB, Robinson J, Mong J, Hsu J, Regillo C, Ho A, Haller JA. Vitrectomy After ocriplasmin for VitreOmacular adhesion Or Macular hole (VAVOOM) study. Br J Ophthalmol. 2016 Sep; 100(9):1211-5.
-
Khan MA, Shahlaee A, Ho AC. Reopening of a Full-Thickness Macular Hole 2 Years After Pharmacologic Closure With Ocriplasmin. JAMA Ophthalmol. 2015 Nov; 133(11):1362-4.
-
Varma R, Haller JA, Kaiser PK. Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials. JAMA Ophthalmol. 2015 Sep; 133(9):997-1004.
-
Kaiser PK, Kampik A, Kuppermann BD, Girach A, Rizzo S, Sergott RC. Safety profile of ocriplasmin for the pharmacologic treatment of symptomatic vitreomacular adhesion/traction. Retina. 2015 Jun; 35(6):1111-27.